Offerings // Aligos Therapeutics, Inc.

ALGS offering history

Every offering-related filing in Aligos Therapeutics, Inc.’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 348 filings back to Jan 16, 2020.

Last executed offering

Feb 12, 2025

8-K — priced deal (shares or notes)

Last registration (announced)

Mar 27, 2025

S-3 — capacity, not a sale

Executed, last 12 months

424B pricings + 8-K 3.02 sales

Registered, last 12 months

S-1/S-3/F-series registrations

Date	Filing		What it means
Apr 3, 2025	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
Apr 3, 2025	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Mar 27, 2025	S-3 →	REGISTERED	S-3 registration — capacity to sell shares, not a sale yet
Feb 12, 2025	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
Nov 18, 2024	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Nov 6, 2024	S-3 →	REGISTERED	S-3 registration — capacity to sell shares, not a sale yet
Nov 28, 2023	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
Nov 27, 2023	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Nov 17, 2023	S-3 →	REGISTERED	S-3 registration — capacity to sell shares, not a sale yet
Oct 25, 2023	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
Nov 19, 2021	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Nov 4, 2021	S-3 →	REGISTERED	S-3 registration — capacity to sell shares, not a sale yet
Jul 1, 2021	424B4 →	EXECUTED	Final prospectus — offering priced (typical for IPOs and marketed share deals)
Jun 30, 2021	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Jun 28, 2021	S-1 →	REGISTERED	S-1 registration — capacity to sell shares, not a sale yet
Oct 19, 2020	424B4 →	EXECUTED	Final prospectus — offering priced (typical for IPOs and marketed share deals)
Oct 15, 2020	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Oct 9, 2020	S-1/A →	REGISTERED	S-1/A registration — capacity to sell shares, not a sale yet
Sep 25, 2020	S-1 →	REGISTERED	S-1 registration — capacity to sell shares, not a sale yet

ALGS offering-related filings from SEC EDGAR, newest first (capped at 40). Each links to the original document.

Two honest limits. (1) A 424B takedown can price shares or notes — EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.

Is a shelf active now? →Do they need money? →Red flags →Full ALGS workspace →

ALGS offering FAQ

When did ALGS last execute an offering?

Per SEC filings, Aligos Therapeutics, Inc.'s most recent priced offering document is a 8-K filed 2025-02-12. Note a 424B takedown can price shares or notes (debt) — the linked document says which.

When did ALGS last announce or register an offering?

The most recent registration is a S-3 filed 2025-03-27. A registration is capacity to sell shares — not a sale.

Does an offering always mean dilution?

Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.

Free to use. No account, no card.